FTO (Freedom to Operate) in the Pharmaceutical Industry
FTO licensing in the pharmaceutical industry deserves special consideration because of the large economic scale of the market, expensive cost of R&D, extremely low success rate, and easy duplication of the drug. Taking these unique aspects into consideration, the author first explaines how to pe...
Saved in:
| Main Author: | |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Nomos Verlagsgesellschaft mbH & Co. KG
2018
|
| Series: | Munich Intellectual Property Law Center - MIPLC
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_48170 | ||
| 005 | 20210211 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20210211s2018 xx |||||o ||| 0|eng d | ||
| 020 | |a /dx.doi.org/10.5771/9783845294018 | ||
| 020 | |a 9783845294018 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a http://dx.doi.org/10.5771/9783845294018 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 100 | 1 | |a Nonaka, Hirotaka |4 auth | |
| 245 | 1 | 0 | |a FTO (Freedom to Operate) in the Pharmaceutical Industry |
| 260 | |b Nomos Verlagsgesellschaft mbH & Co. KG |c 2018 | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Munich Intellectual Property Law Center - MIPLC | |
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a FTO licensing in the pharmaceutical industry deserves special consideration because of the large economic scale of the market, expensive cost of R&D, extremely low success rate, and easy duplication of the drug. Taking these unique aspects into consideration, the author first explaines how to perform a good FTO search and conclude an appropriate FTO licensing agreement, and then points out two issues; (i) the issue of FTO licensing and EU competition, especially the unreasonable application of the Guideline, and (ii) the issue of FTO licensing and differentiating between a bio venture company and a pharmaceutical company. Solutions for these issues are proposed. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by-nc-nd/4.0/ |2 cc |4 https://creativecommons.org/licenses/by-nc-nd/4.0/ | ||
| 546 | |a English | ||
| 653 | |a FTO | ||
| 653 | |a pharmaceutical industry | ||
| 653 | |a Freedom to Operate | ||
| 653 | |a antitrust law | ||
| 653 | |a FTO-licensing market | ||
| 653 | |a Patent | ||
| 653 | |a License | ||
| 653 | |a Pharmaceutical | ||
| 653 | |a EU competition law | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://www.nomos-elibrary.de/10.5771/9783845294018 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/48170 |7 0 |z DOAB: description of the publication |